Renal Tubular Acidosis

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2436 times

Chapter 523 Renal Tubular Acidosis

Renal tubular acidosis (RTA) is a disease state characterized by a normal anion gap (hyperchloremic) metabolic acidosis in the setting of normal or near-normal glomerular filtration rate. There are 4 main types: proximal (type II) RTA, classic distal (type I) RTA, hyperkalemic (type IV) RTA, and combined proximal and distal (type III). Proximal RTA results from impaired bicarbonate reabsorption and distal RTA from failure to secrete acid. Either of these defects may be inherited and persistent from birth or acquired, as is seen more commonly in clinical practice.

Normal Urinary Acidification

Kidneys contribute to acid-base balance by reabsorption of filtered bicarbonate (HCO3) and excretion of hydrogen ion (H+) produced every day. Hydrogen ion secretion from tubule cells into the lumen is key in the reabsorption of HCO3, formation of titratable acidity (H+ bound to buffers such as HPO42−), and formation of ammonium ions (NH4+). Because loss of filtered HCO3 is equivalent to addition of H+ to the body, all filtered bicarbonate should be absorbed before dietary H+ can be excreted. About 90% of filtered bicarbonate is absorbed in the proximal tubule and the remaining 10% in the distal segments, mostly thick ascending limb and outer medullary collecting tubule (CT) (Fig. 523-1). In the proximal tubule and thick ascending limb of the loop of Henle (TAL) H+ from water is secreted by the Na+-H+ exchanger on the luminal membrane. H+ combines with filtered bicarbonate resulting in the formation of H2CO3, which splits into water and CO2 in the presence of carbonic anhydrase (CA) IV. CO2 diffuses freely back into the cell, combines with OH (from H2O) to form HCO3 in the presence of CA II, and returns to systemic circulation via the Na+-3HCO3 cotransporter situated at the basolateral membrane of the cell. In the CT, H+ is secreted into lumen by H+ATPase (adenosine triphosphatase) and H-CO3 is returned to systemic circulation by HCO3-Cl exchanger located on the basolateral membrane. The H+ secreted proximally and distally in excess of the filtered HCO3 is excreted in the urine either as titratable acid or as NH4+.

523.1 Proximal (Type II) Renal Tubular Acidosis

Rajasree Sreedharan and Ellis D. Avner

Pathogenesis

Proximal RTA can be inherited and persistent from birth or occur as a transient phenomenon during infancy. Although rare, it may be primary and isolated. Proximal RTA usually occurs as a component of global proximal tubular dysfunction or Fanconi syndrome, which is characterized by low molecular weight proteinuria, glycosuria, phosphaturia, aminoaciduria, and proximal RTA. The causes of proximal RTA and Fanconi syndrome are outlined in Table 523-1. Many of these causes are inherited disorders. In addition to cystinosis and Lowe syndrome, autosomal recessive and dominant pRTA are addressed further in this section. Other inherited forms of Fanconi syndrome include galactosemia (Chapter 81.2), hereditary fructose intolerance (Chapter 81.3), tyrosinemia (Chapter 79.2), and Wilson disease (Chapter 349.2). Dent disease, or X-linked nephrolithiasis, is discussed in Chapter 525.3. In children, an important form of secondary Fanconi syndrome is exposure to ifosfamide, a component of many treatment regimens for Wilms tumor and other solid tumors.

Table 523-1 COMMON CAUSES OF RENAL TUBULAR ACIDOSIS

PROXIMAL RENAL TUBULAR ACIDOSIS

Primary

Secondary

DISTAL RENAL TUBULAR ACIDOSIS

Primary

Secondary

HYPERKALEMIC RENAL TUBULAR ACIDOSIS

Primary

Secondary

Cystinosis

Cystinosis is a systemic disease caused by a defect in the metabolism of cystine, which results in accumulation of cystine crystals in most of the major organs of the body, notably the kidney, liver, eye, and brain. It occurs at an incidence of 1 : 100,000-1 : 200,000. In certain populations, such as French Canadians, the incidence is much higher. At least 3 clinical patterns have been described. Young children with the most severe form of the disease (infantile or nephropathic cystinosis) present in the first 2yr of life with severe tubular dysfunction and growth failure. If the disease is not treated, the children develop end-stage renal disease by the end of their 1st decade. A milder form of the disease manifests in adolescents and is characterized by less-severe tubular abnormalities and a slower progression to renal failure. A benign adult form with no renal involvement also exists.

Cystinosis is caused by mutations in the CTNS gene, which encodes a novel protein, cystinosin. Cystinosin is thought to be an H+-driven lysosomal cystine transporter. Genotype-phenotype studies demonstrate that patients with severe nephropathic cystinosis carry mutations that lead to complete loss of cystinosin function. Patients with milder clinical disease have mutations that lead to expression of partially functional protein. Patients with nephropathic cystinosis present with clinical manifestations reflecting their pronounced tubular dysfunction and Fanconi syndrome, including polyuria and polydipsia, growth failure, and rickets. Fever, caused by dehydration or diminished sweat production, is common. Patients are typically fair skinned and blond because of diminished pigmentation. Ocular presentations include photophobia, retinopathy, and impaired visual acuity. Patients also can develop hypothyroidism, hepatosplenomegaly, and delayed sexual maturation. With progressive tubulointerstitial fibrosis, renal insufficiency is invariant.

The diagnosis of cystinosis is suggested by the detection of cystine crystals in the cornea and confirmed by measurement of increased leukocyte cystine content. Prenatal testing is available for at-risk families.

Treatment of cystinosis is directed at correcting the metabolic abnormalities associated with Fanconi syndrome or chronic renal failure. In addition, specific therapy is available with cysteamine, which binds to cystine and converts it to cysteine. This facilitates lysosomal transport and decreases tissue cystine. Oral cysteamine does not achieve adequate levels in ocular tissues, so additional therapy with cysteamine eyedrops is required. Early initiation of the drug can prevent or delay deterioration of renal function. Patients with growth failure that does not improve with cysteamine might benefit from treatment with growth hormone. Kidney transplantation is a viable option in patients with renal failure. With prolonged survival, additional complications may become evident, including central nervous system abnormalities, muscle weakness, swallowing dysfunction, and pancreatic insufficiency. It is unclear whether long-term cysteamine therapy decreases these complications.

523.2 Distal (Type I) Renal Tubular Acidosis

Rajasree Sreedharan and Ellis D. Avner

Pathogenesis

As with proximal RTA, distal RTA can be sporadic or inherited. It can also occur as a complication of inherited or acquired diseases of the distal tubules. Primary or secondary causes of distal RTA can result in damaged or impaired functioning of one or more transporters or proteins involved in the acidification process, including the H+/ATPase, the HCO3/Cl anion exchangers, or the components of the aldosterone pathway. Because of impaired hydrogen ion excretion, urine pH cannot be reduced to <5.5, despite the presence of severe metabolic acidosis. Loss of sodium bicarbonate distally, owing to lack of H+ to bind to in the tubular lumen (see Fig. 523-1), results in increased chloride absorption and hyperchloremia. Inability to secrete H+ is compensated by increased K+ secretion distally, leading to hypokalemia. Hypercalciuria is usually present and can lead to nephrocalcinosis or nephrolithiasis. Chronic metabolic acidosis also impairs urinary citrate excretion. Hypocitraturia further increases the risk of calcium deposition in the tubules. Bone disease is common, resulting from mobilization of organic components from bone to serve as buffers to chronic acidosis.

523.3 Hyperkalemic (Type IV) Renal Tubular Acidosis

Rajasree Sreedharan and Ellis D. Avner

Diagnostic Approach

The first step in the evaluation of a patient with suspected RTA is to confirm the presence of a normal anion gap metabolic acidosis, identify electrolyte abnormalities, assess renal function, and rule out other causes of bicarbonate loss such as diarrhea (Chapter 52). Metabolic acidosis associated with diarrheal dehydration is extremely common, and acidosis generally improves with correction of volume depletion. Patients with protracted diarrhea can deplete their total-body bicarbonate stores and can have persistent acidosis despite apparent restoration of volume status. In instances where a patient has a recent history of severe diarrhea, full evaluation for RTA should be delayed for several days to permit adequate time for reconstitution of total-body bicarbonate stores. If acidosis persists beyond a few days in this setting, additional studies are indicated.

Serum electrolytes, blood urea nitrogen, calcium, phosphorus, creatinine, and pH should be obtained by venous puncture. Traumatic blood draws (such as heel stick specimens), small volumes of blood in “adult-size” specimen collection tubes, or prolonged specimen transport time at room temperature can lead to falsely low bicarbonate levels, often in association with an elevated serum potassium value. True hyperkalemic acidosis is consistent with type IV RTA, whereas the finding of normal or low potassium suggests type I or II. The blood anion gap should be calculated using the formula [Na+] − [Cl + HCO3]. Values of <12 demonstrate the absence of an anion gap. Values of >20 are highly suggestive of the presence of an anion gap. If such an anion gap is found, then other diagnoses (lactic acidosis, inborn errors of metabolism, ingested toxins) should be investigated. If tachypnea is noted, evaluation of an arterial blood gas might help to rule out the possibility of a mixed acid-base disorder primarily involving respiratory and metabolic components. A detailed history, with particular attention to growth and development, recent or recurrent diarrheal illnesses, and family history of mental retardation, failure to thrive, end-stage renal disease, infant deaths, or miscarriages is essential. Physical examination should determine growth parameters and volume status as well as the presence of any dysmorphic features suggesting an underlying syndrome.

Once the presence of a non–anion gap metabolic acidosis is confirmed, urine pH can help distinguish distal from proximal causes. A urine pH <5.5 in the presence of acidosis suggests proximal RTA, whereas patients with distal RTA typically have a urine pH >6.0. The urine anion gap ([urine Na+ + urine K+] − urine Cl) is sometimes calculated to confirm the diagnosis of distal RTA. A positive gap suggests a deficiency of ammoniagenesis and, thus, the possibility of a distal RTA. A negative gap is consistent with proximal tubule bicarbonate wasting (gastrointestinal bicarbonate wasting). A urinalysis should also be obtained to determine the presence of glycosuria, proteinuria, or hematuria, suggesting more global tubular damage or dysfunction. Random or 24-hr urine calcium and creatinine measurements will identify hypercalciuria. Renal ultrasonography should be performed to identify underlying structural abnormalities such as obstructive uropathies as well as to determine the presence of nephrocalcinosis (Fig. 523-2).

523.4 Rickets Associated with Renal Tubular Acidosis

Russell W. Chesney

Rickets may be present in primary RTA, particularly in type II or proximal RTA. Hypophosphatemia and phosphaturia are common in the renal tubular acidoses, which are also characterized by hyperchloremic metabolic acidosis, various degrees of bicarbonaturia, and, often, hypercalciuria and hyperkaluria. Bone demineralization without overt rickets usually is detected in type I and distal RTA. This metabolic bone disease may be characterized by bone pain, growth retardation, osteopenia, and, occasionally, pathologic fractures. Although acute metabolic acidosis in vitamin D–deficient animals can impair the conversion of 25-hydroxyvitamin D (25[OH]D) to 1,25-dihydroxyvitamin D (1,25[OH]2D), resulting in reduced levels of this active metabolite, the circulating levels of 1,25(OH)2D in patients with either type of RTA are normal. If patients with RTA have chronic renal insufficiency, serum 1,25(OH)2D levels are reduced in relation to the degree of renal impairment.

Bone demineralization in distal RTA probably relates to dissolution of bone because the calcium carbonate in bone serves as a buffer against the metabolic acidosis due to the hydrogen ions retained by patients with RTA.

Administration of sufficient bicarbonate to reverse acidosis reverses bone dissolution and the hypercalciuria that is common in distal RTA. Proximal RTA is treated with both bicarbonate and oral phosphate supplements to heal rickets. Doses of phosphate similar to those used in familial hypophosphatemia or Fanconi syndrome may be indicated. Vitamin D is required to offset the secondary hyperparathyroidism that complicates oral phosphate therapy. Following therapy, growth in patients with type II (proximal) RTA is greater than in patients with primary Fanconi syndrome.

Bibliography

Alper SL. Genetic diseases of acid-base transporters. Annu Rev Physiol. 2002;64:899-923.

Chan JCM, Scheinman JI, Roth KS. Renal tubular acidosis. Pediatr Rev. 2001;22:277-286.

Fry AC, Karet FE. Inherited renal acidoses. Physiology. 2007;22:202-211.

Fulop M, Mackay M. Renal tubular acidosis, Sjögren syndrome, and bone disease. Arch Intern Med. 2004;164:905-909.

Gahl WA. Cystinosis. In: Avner ED, Harmon WE, Niaudet P, et al, editors. Pediatric nephrology. ed 6. Heidelberg, Germany: Springer-Verlag; 2009:1019-1038.

Gahl WA. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr. 2003;162(Suppl 1):S38-S41.

Hsu SY, Tsai IJ, Tsau YK. Comparison of growth in primary Fanconi syndrome and proximal renal tubular acidosis. Pediatr Nephrol. 2005;20:460.

Igarashi T. Fanconi syndrome. In: Avner ED, Harmon WE, Niaudet P, et al, editors. Pediatric nephrology. ed 6. Heidelberg, Germany: Springer-Verlag; 2009:1039-1068.

Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug-induced Fanconi’s syndrome. Am J Kidney Dis. 2003;41:292-309.

Kalatzis V, Antignac C. New aspects of the pathogenesis of cystinosis. Pediatr Nephrol. 2003;18:207-215.

Magen D, Berger L, Coady MJ, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med. 2010;362(12):1102-1108.

Nicoletta JA, Schwartz GJ. Distal renal tubular acidosis. Curr Opin Pediatr. 2004;16:194-198.

Pongchaiyakul C, Domrongkitchaiporn S, Stichantrakul W, et al. Incomplete renal tubular acidosis and bone mineral density: a population survey in a area of endemic renal tubular acidosis. Nephrol Dial Transplant. 2004:3029-3033.

Prie D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med. 2010;362:2399-2409.

Quigley R. Renal tubular acidosis. In: Avner ED, Harmon WE, Niaudet P, et al, editors. Pediatric nephrology. ed 6. Heidelberg, Germany: Springer-Verlag; 2009:979-1004.

Rodriguez-Soriano J. New insights into the pathogenesis of renal tubular acidosis—from functional to molecular studies. Pediatr Nephrol. 2000;14:1121-1136.

Rose BD, Post TW. Regulation of acid-base balance. In Clinical physiology of acid-base and electrolyte disorders, ed 5, New York: McGraw-Hill; 2001:325-371.

Wappner RS. Lowe syndrome. In GeneClinics: Clinical Genetic Information Resource (database online), http://www.geneclinics.org/.

Wuhl E, Haffner D, Offner G, et al. Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr. 2001;138:880-887.